There is a company in the quantum computing sector that generated about $7 million in revenue last year. Not $7 billion. Seven million — roughly what a mid-sized car dealership turns over. Its market capitalization is measured in the billions.
That is not a typo, and it is not an outlier. It is the entire quantum trade in one sentence: extraordinary science, spectacular valuations, and almost no revenue underneath. IonQ, the largest pure-play by sales, is valued near $19 billion against roughly $187 million in trailing revenue. Rigetti’s sales actually shrank last year. And yet these stocks have doubled, tripled, and doubled again — because in 2026, something genuinely changed. Quantum computing crossed the line from physics experiment to engineering discipline. The error-correction problem that stalled the field for thirty years is, for the first time, being solved on real hardware.
So both things are true at once: the technology is real and arriving, and most people buying these stocks today will lose money. Reconciling those two facts is the entire game. Getting it wrong means either missing the defining compute platform of the next two decades, or lighting your capital on fire on a story stock that dilutes you into oblivion.
Below, we lay out the free half of the map: why 2026 is the true inflection point, and the three questions that separate the foundations from the lottery tickets.
Free section (this post)
Why 2026 is the real inflection point — the “below threshold” breakthrough that took thirty years, and why the field just quietly changed category.
The valuation problem, in plain numbers — what these companies actually earn versus what the market says they’re worth.
The three-question filter — how we separate a genuine foundation from a lottery ticket, before we ever look at a chart.
The mistake almost everyone is making — why treating a ten-year thesis like a ten-week trade is the fastest way to be right about quantum and still lose money.
Premium section (subscribers)
The specific positions we hold — the names we’re actually in, and the one-line thesis behind each.
How we size a ten-year bet — the position-sizing framework that lets a 60% drawdown happen without ending the thesis (these stocks moved 30%+ in a single session this year).
The dilution math that quietly destroys quantum shareholders — the red flags we screen for, and the specific mechanism that erodes your stake even when the technology works.
The 2027 catalyst nobody is pricing — the dated regulatory deadline that turns “quantum is a decade away” from a reason to wait into a reason to act now.
Our watchlist tiers — foundations, options, and avoid — mapped to milestones, not narratives.
For most of its history, quantum computing had a single, unforgiving problem: qubits are fragile. They lose their quantum state at the faintest disturbance, and the more you added, the more errors you accumulated. Scaling the machine up made it worse, not better. That’s the wall the field spent three decades staring at.
The breakthrough — the one that actually matters — is that error rates can now be made to fall as the machine scales up rather than spiral out of control. Researchers call this the “below threshold” result, and it’s the milestone the entire field chased since the 1990s. It proved something that had until recently been only theoretical: that fault-tolerant quantum computing is physically achievable with real hardware, not just on a whiteboard.
Since then, the milestones have come quickly. Multiple companies have now demonstrated verified logical qubits — bundles of noisy physical qubits stitched together so that errors get corrected faster than they appear. One neutral-atom group published a result of 96 logical qubits from 448 physical atoms with below-threshold error suppression. Company roadmaps now run from today’s handful of logical qubits toward the thousands needed for genuinely useful work, with named systems and dated targets stretching across the decade.
Here’s the reframe that matters for investors: in 2026, quantum error correction stopped being a physics curiosity and became an engineering discipline. That’s a category change. Physics problems are binary — either the universe allows it or it doesn’t. Engineering problems are about time, money, and execution. The field has crossed from “will this ever work?” to “how fast can we build it, and who builds it best?” That is a fundamentally more investable question — and also a fundamentally more dangerous one, because engineering timelines slip, and speculative markets do not forgive slippage.
Now the uncomfortable half. The technology inflection is real. The valuations attached to it are, by any conventional measure, detached from the businesses underneath.
Consider the three best-known pure-plays. IonQ, the revenue leader, carries a market capitalization near $19 billion against roughly $187 million in trailing revenue and deeply negative EBITDA. Rigetti trades at a multi-billion-dollar valuation on roughly $7 million in annual revenue — and that revenue declined year over year. D-Wave sits in a similar posture: minimal revenue, meaningful losses, an enormous multiple.
These are not value stocks with a growth kicker. They are, functionally, long-dated call options on a technology that may not produce commercially decisive results until the back half of the decade. Useful chemistry, cryptography, and large-scale optimization workloads remain a late-decade story. That gap — between today’s science and tomorrow’s revenue — is precisely why these names trade like lottery tickets, lurching 30% or more in a single session on a headline.
None of that makes them uninvestable. It makes them a specific kind of investment that has to be approached in a specific way — which is the entire point of this edition. Buying a decade-long option as if it were a conviction position in a profitable compounder is how portfolios get destroyed in exactly this kind of setup: a stretched multiple, thin or shrinking sales, and a company that has to keep issuing stock to stay alive.
Before we look at a single price chart, every quantum name we consider has to survive three questions. This is the free version of our framework — the filter that separates a foundation from a lottery ticket.
Question 1: Is there real revenue today, or only a roadmap? A company with even modest but growing commercial revenue is playing a different game from one whose entire value rests on a slide deck. Growing revenue means real customers are extracting real value now, which de-risks the timeline. Shrinking or non-existent revenue means you are betting purely on a future that may arrive late — or not at all.
Question 2: Does the technology roadmap have credible, dated, and met milestones? Every quantum company publishes an ambitious roadmap. The signal isn’t the ambition — it’s the track record of hitting the previous milestones on time. A company that has delivered each prior target on schedule has earned some benefit of the doubt on the next one. A company whose fab timelines have repeatedly slipped has told you something important about the next promise.
Question 3: How is it funded — and at whose expense? This is the question retail investors almost always skip, and it’s the one that quietly determines your outcome. A company burning cash has to fund itself somehow, and for most pure-plays that means issuing new shares — sometimes continuously. Even if the technology works perfectly, your slice of the pie can shrink year after year. Understanding how a company plugs its cash burn is often more decisive for your return than understanding its qubit architecture.
Run those three questions across the sector and something clarifying happens: the names sort themselves into tiers that have very little to do with which stock ran hardest last month.
The single most expensive error in quantum right now isn’t picking the wrong architecture. It’s treating a ten-year thesislike a ten-week trade.
It shows up in three ways. Buying the loudest name because it’s the one in the headlines. Sizing a speculative, binary-outcome position as if it were a high-conviction bet on a proven business. And ignoring that a company can be scientifically brilliant and still dilute its shareholders every single year to keep the lights on.
In quantum, the distance between “right about the technology” and “made money on the technology” is enormous — and it’s where most portfolios go to die. You can be completely correct that fault-tolerant quantum computing is coming, correct about roughly when, correct about which physics wins — and still lose money, because you sized it wrong, bought it at the wrong multiple, or got diluted out of your gains while you waited.
Closing that gap is not about conviction. It’s about structure: which names, at what size, funded how, held against which dated catalysts. That structure is exactly what the rest of this edition lays out.
The free half gives you the map. The premium half is where we actually deploy capital: the specific positions we holdand the thesis behind each, the sizing framework that lets a brutal drawdown happen without ending the thesis, the dilution red flags we screen for, and the dated 2027 regulatory catalyst we think the market is badly underpricing.
Subscribe to Tech Economics Premium to read the full edition — and to unlock every deep-dive in our archive, where we identify tomorrow’s tech giants before they become obvious.
This is research on what we do with our own capital, not personalized investment advice. Quantum names are among the most volatile and speculative assets in the market — size accordingly.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.